These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

714 related items for PubMed ID: 8198025

  • 1. Prevention of restenosis after coronary balloon angioplasty: rationale and design of the Fluvastatin Angioplasty Restenosis (FLARE) Trial. The FLARE Study Group.
    Foley DP, Bonnier H, Jackson G, Macaya C, Shepherd J, Vrolix M, Serruys PW.
    Am J Cardiol; 1994 May 26; 73(14):50D-61D. PubMed ID: 8198025
    [Abstract] [Full Text] [Related]

  • 2. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial.
    Serruys PW, Foley DP, Jackson G, Bonnier H, Macaya C, Vrolix M, Branzi A, Shepherd J, Suryapranata H, de Feyter PJ, Melkert R, van Es GA, Pfister PJ.
    Eur Heart J; 1999 Jan 26; 20(1):58-69. PubMed ID: 10075142
    [Abstract] [Full Text] [Related]

  • 3. Fluvastatin for the prevention of restenosis after coronary balloon angioplasty: angiographic and methodological background of the fluvastatin angioplasty restenosis trial.
    Foley DP, Serruys PW.
    Br J Clin Pract Suppl; 1996 Jan 26; 77A():40-53. PubMed ID: 8729590
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The influence of plasma lipoprotein (a) on angiographic restenosis and coronary events in patients undergoing planned coronary balloon angioplasty. Ancillary analysis of the Fluvastatin Angioplasty Restenosis (FLARE) trial.
    Lloyd GW, Jackson G, Foley DP, Boersma E, Shepherd J, Serruys PW.
    Atherosclerosis; 2001 Oct 26; 158(2):445-54. PubMed ID: 11583725
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the Probucol Angioplasty Restenosis Trial.
    Yokoi H, Daida H, Kuwabara Y, Nishikawa H, Takatsu F, Tomihara H, Nakata Y, Kutsumi Y, Ohshima S, Nishiyama S, Seki A, Kato K, Nishimura S, Kanoh T, Yamaguchi H.
    J Am Coll Cardiol; 1997 Oct 26; 30(4):855-62. PubMed ID: 9316509
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Restenosis and clinical outcome in patients treated with amlodipine after angioplasty: results from the Coronary AngioPlasty Amlodipine REStenosis Study (CAPARES).
    Jørgensen B, Simonsen S, Endresen K, Forfang K, Vatne K, Hansen J, Webb J, Buller C, Goulet G, Erikssen J, Thaulow E.
    J Am Coll Cardiol; 2000 Mar 01; 35(3):592-9. PubMed ID: 10716459
    [Abstract] [Full Text] [Related]

  • 10. Influence of coronary vessel size on renarrowing process and late angiographic outcome after successful balloon angioplasty.
    Foley DP, Melkert R, Serruys PW.
    Circulation; 1994 Sep 01; 90(3):1239-51. PubMed ID: 8087933
    [Abstract] [Full Text] [Related]

  • 11. Background and methods for the lovastatin restenosis trial after percutaneous transluminal coronary angioplasty. The Lovastatin Restenosis Trial Study Group.
    Weintraub WS, Boccuzzi SJ, Brown CL, Cohen CL, Hirsch LJ, King SB, Alexander RW.
    Am J Cardiol; 1992 Aug 01; 70(3):293-9. PubMed ID: 1632391
    [Abstract] [Full Text] [Related]

  • 12. The Lipoprotein and Coronary Atherosclerosis Study (LCAS): design, methods, and baseline data of a trial of fluvastatin in patients without severe hypercholesterolemia.
    West MS, Herd JA, Ballantyne CM, Pownall HJ, Simpson S, Gould L, Gotto AM.
    Control Clin Trials; 1996 Dec 01; 17(6):550-83. PubMed ID: 8974213
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. An economic evaluation of fluvastatin used for the prevention of cardiac events following successful first percutaneous coronary intervention in the UK.
    Scuffham PA, Chaplin S.
    Pharmacoeconomics; 2004 Dec 01; 22(8):525-35. PubMed ID: 15217308
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Failure of epoprostenol (prostacyclin, PGI2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomised placebo controlled trial.
    Gershlick AH, Spriggins D, Davies SW, Syndercombe Court YD, Timmins J, Timmis AD, Rothman MT, Layton C, Balcon R.
    Br Heart J; 1994 Jan 01; 71(1):7-15. PubMed ID: 8297699
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effects of lovastatin on progression of non-dilated and dilated coronary segments and on restenosis in patients after PTCA. The cholesterol lowering atherosclerosis PTCA trial (CLAPT).
    Kleemann A, Eckert S, von Eckardstein A, Lepper W, Schernikau U, Gleichmann U, Hanrath P, Fleck E, Neiss A, Kerber S, Assmann G, Breithardt G, CLAPT Study.
    Eur Heart J; 1999 Oct 01; 20(19):1393-406. PubMed ID: 10487800
    [Abstract] [Full Text] [Related]

  • 19. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty.
    Tsuchikane E, Fukuhara A, Kobayashi T, Kirino M, Yamasaki K, Kobayashi T, Izumi M, Otsuji S, Tateyama H, Sakurai M, Awata N.
    Circulation; 1999 Jul 06; 100(1):21-6. PubMed ID: 10393676
    [Abstract] [Full Text] [Related]

  • 20. [Low molecular weight heparin, reviparin, after PTCA: results of a randomized double-blind, standard heparin and placebo controlled multicenter study (REDUCE Study].
    Preisack MB, Baildon R, Eschenfelder V, Foley D, Garcia E, Kaltenbach M, Meisner C, Selbmann HK, Serruys PW, Shiu MF, Sujatta M, Bonan R, Karsch KR.
    Z Kardiol; 1997 Aug 06; 86(8):581-91. PubMed ID: 9417748
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.